中国药学杂志
    
           首页  |  期刊介绍  |  编 委 会  |  投稿指南  |  期刊订阅  |  广告服务  |  会议信息  |  联系我们  | 
�й�ҩѧ��־ 2015, Vol. 50 Issue (7) :646-649    DOI: 10.11669/cpj.2015.07.017
ҩ�����ٴ� ����Ŀ¼ | ����Ŀ¼ | ������� | �߼����� << | >>
1���ѳ������ܰͽ�˹���Ѫ͸���߸���ҩ�����Ƶ�ҩѧ��Ԥ
��ѩ1,2, �½�1*, ����1
1.��ɽ��ѧ������һҽԺҩѧ��,���� 510080;
2.��ɽ��ѧҩѧԺ,���� 510006
ZHOU Xue1,2, CHEN Jie1*, GAO Xiang1
1. Department of Pharmacy, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China;
2. School of Pharmaceutical Science, Sun Yat-sen University, Guangzhou 510006, China

Download: PDF (709KB)   HTML (1KB)   Export: BibTeX or EndNote (RIS)      Supporting Info
ժҪ Ŀ�� �ٴ�ҩʦͨ����1�������⺱���������ѳ������󸴷����ܰͽ��Ѫ͸���ߵĿ���˺ͻ��Ʒ�������ҩѧ��Ԥ,�ﵽ�˽Ϻõ�����Ч�������� �ٴ�ҩʦ��ѪҺ͸�����߻����뿹������Ƶĸ��������,�����Լ�ҩѧרҵ֪ʶ,���Ĺ������������,ȷ�����ߵĿ���˼����Ʒ���,�Ż���������,���Ի��߽������벬��Ũ�Ȳⶨ��������Ӧ��ҩѧ�໤,����AUC,�Ż���һ�θ�ҩ��������� ȫԺ���ィ�黼���Ƚ��п��������,���ܰͽ����������ƺ��ٽ����ѳ������ơ��ٴ�ҩʦ��ҽʦ�������ۻ������Ż����Ʒ���Ϊ:����ƽ0.45 g,1��1��,���ո���;������,0.3 g,1��1��,͸��������͸�����ҩ;�Ұ�����0.75 g,ÿ��һ��������͸�����ҩ;����Calvert��ʽ���㿨��0.15 g,��������ɼ��0.15 g��m-2���ơ���ҩ����24 h�����ѪҺ͸��,ѪҺ͸��ά��3 h,���벬��Ũ�Ȳⶨ,���Ƶ�2~4�Ƴ̷���Ϊ��ɼ��0.15 g��m-2,����0.166 g,��ҩ��ʽͬ��һ�Ƴ̡����������ƹ�����,���������Բ�����Ӧ,��������ƺͻ��ƾ�ȡ�ýϺ���Ч,�һ������������á����� �ٴ�ҩʦ����ҩ���ҩ��ѧ��ҩЧѧ�ص�,��ϻ��߲����������,Ϊ�������������Ʒ�����Ԥ��������Ӧ���������Ч��,ʹ���߻��������ơ�
Service
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
Email Alert
RSS
�����������
��ѩ
�½�*
����
�ؼ����� �ٴ�ҩʦ   ���������   �ѳ�������   ѪҺ͸��   ҩѧ��Ԥ     
Abstract�� OBJECTIVE To carry out pharmaceutical intervention on a complicated patient with oophoroma, lymphatic tuberculosis and regular hemodialysis to achieve better therapeutic effect.METHODS Clinical pharmacists developed anti-tuberculosis and anti-tumor schemes, optimized carboplatin dosage, determined free platinum concentrations, calculated AUC of platinum and monitored adverse drug effect by using their pharmaceutical expertise.RESULTS Hospital-wide consultation recommended this patient with prior anti-TB treatment, and continue with ovarian cancer chemotherapy after somewhat lymphatic tuberculosis is controlled. The final anti-TB treatment scheme is rifampicin 0.45 g, once daily, morning empty stomach; isoniazid, 0.3 g, once daily, administrated after dialysis on dialysis day; ethambutol, 0.75 g, administrated after each dialysis. The first course of anti-tumor schemes is paclitaxel 0.15 g�m-2 and carboplatin 0.15 g calculated according to Calvert formula, dialysis was carried 24 h later and kept 3 h. Then determined free platinum concentrations, and calculated out the following 2nd-4th courses of anti-tumor treatment, which is paclitaxel 0.15 g�m-2 and carboplatin 0.166 g. The patient had no significant adverse reactions throughout the course of therapy, and anti-tuberculosis and anti-tumor treatment achieved good effect and well tolerance by patients.CONCLUSIONS According to pharmacokinetic and pharmacodynamic characteristics of the drug combined with patient pathophysiological conditions, clinical pharmacist designs the best treatment schemes for patients, prevents adverse reactions and held treatment monitoring.This patient can get the best treatment as a result.
Keywords�� clinical pharmacist,   anti-tuberculosis,   anti-ovarian cancer chemotherapy,   hemodialysis,   pharmaceutical intervention     
�ո�����: 2014-05-19;
ͨѶ���� �½�,��,������ҩʦ �о�����:�ٴ�ҩѧ Tel:(020)87755766 E-mail:chenjiezs@163.com   
���߼��: ��ѩ,Ů,˶ʿ�о��� �о�����:�ٴ�ҩѧ
���ñ���:   
��ѩ, , �½�*�� .1���ѳ������ܰͽ�˹���Ѫ͸���߸���ҩ�����Ƶ�ҩѧ��Ԥ[J]  �й�ҩѧ��־, 2015,V50(7): 646-649
ZHOU Xue-, , CHEN Jie-* etc .Pharmaceutical Intervention on a Complicated Patient with Oophoroma, Lymphatic Tuberculosis and Regular Hemodialysis[J]  Chinese Pharmaceutical Journal, 2015,V50(7): 646-649
��
[1] VINCENT L V, HASSANE I, GILBERT D. Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure. Clin Pharmacokinet,2005,44(3):221-235. [2] LEUNG G K Y, TAM P Y W, TING R H. Isoniazid toxicity in hemodialysis patients . Am Soc Nephrol, 2002,13(Suppl 1):464A. [3] ALTIPARMAK M R, PAMUK O N, PAMUK G E, et al. Is isoniazid ototoxic in patients undergoing hemodialysis. Nephron, 2002,92(2):478-480. [4] MAGDI M H, JAAP M M, HAYSAM R. Tuberculosis and chronic renal disease . Seminars in Dialysis,2003, 16(1):38-44. [5] LIU Z W, HU Z H, CAI Y Y. The combined effect of isoniazid and rifampicin on the activities of CYP4501A2 and CYP4503A4 in primary hepatocytes from healthy human adults . Chin J Tuberc Respir Dis, 28(11):785-788. [6] BENNETT W M. Guide to drug dosage in renal failure. Clin Pharmacokinet, 1988,15(5):326-354. [7] MALONE R S, FISH D N, SPIEGEL D M, et al. The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol . Am J Respir Crit Care Med, 1999,159(5):1580-1584. [8] YOSHIDA H, SUMI T, ABE K,et al. Pharmacokinetics of paclitaxel and carboplatin in a hemodialysis patient with advanced ovarian cancer. Eur J Gynaecol Oncol,2009,30(5):583-585. [9] YOKOYAMA Y, FUTAGAMI M, HIGUCHI T, et al. Pharmacokinetic analysis of paclitaxel and carboplatin in a patient with advanced ovarian cancer during hemodialysis--case report. Eur J Gynaecol Oncol, 2006, 27(4):437-439. [10] CALVERT A H, NEWELL D R, GUMBRELL L A, et al. Carboplatin dosage:Prospective evaluation of a simple formula based on renal function. J Clin Oncol,1989,7(11):1748-1756. [11] KODAMA J, SASAKI A, MASAHIRO S,et al. Pharmacokinetics of combination chemotherapy with paclitaxel and carboplatin in a patient with advanced epithelial ovarian cancer undergoing hemodialysis. Oncol Lett,2010, 1(3):511-513. [12] WATANABE M, AOKI Y, TOMITA M,et al. Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer. Gynecol Oncol,2002, 84(2):335-338. [13] JEYABALAN N, HIRTE H W, MOENS F. Treatment of advanced ovarian carcinoma with carboplatin and paclitaxel in a patient with renal failure . Int J Gynecol Cancer, 2000, 10(6):463-468. [14] CHATELUT E, ROSTAING L, GUALANO V, et al. Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency. Nephron, 1994, 66(2):157-161. [15] OGURI T, SHIMOKATA T, INADA M,et al. Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis. Cancer Chemother Pharmacol,2010, 66(4):813-817.
[1] ���ǻ�a,������a,����a,*,��ΰ��b,�����b.5�����¸�Τ������С���𺦼̷��������֢��ҩѧ�໤[J]. �й�ҩѧ��־, 2015,50(8): 727-730
[2] ������a,����b,��ӱ,����a.1���ΰ��ϲ�������ʹ���ߵ�ֹʹ���Ƽ໤[J]. �й�ҩѧ��־, 2015,50(5): 460-462
[3] ��ӳ��,�Ż۷�,��޷�,������,����*.��������֢�໤���ٴ�ҩʦ����ʵ�������[J]. �й�ҩѧ��־, 2014,49(8): 693-694
[4] ��··,����,�ɱ���.����ҩѧרҵ���˲Ž����ĸ������[J]. �й�ҩѧ��־, 2014,49(7): 622-624
[5] ������,����,��Ӣ,��Ө,������*.���ڶ�ͯ�����ص�Ķ����ٴ�ҩʦ����ģʽ̽��[J]. �й�ҩѧ��־, 2014,49(20): 1864-1866
[6] �Ž�������ï��*���ٳ������������.���Ͽ�������Ľ�����ʵ��[J]. �й�ҩѧ��־, 2014,49(16): 1476-1480
[7] ����ΰ, л�, ��ٻ, ����.ijԺ���򲡻���סԺ��ҩ�໥���÷���[J]. �й�ҩѧ��־, 2014,49(11): 944-947
[8] �Ƽ�, ÷����, ��־��*.���򲡻��߹�����ҩѧ����ģʽ̽��[J]. �й�ҩѧ��־, 2014,49(11): 951-954
[9] ������,�Ա�a*,÷��a,��ΰb.һ��Χ������������Ӫ��֧�����Ƶ�ҩѧ����[J]. �й�ҩѧ��־, 2013,48(5): 398-400
[10] ����*���������������С����Ԭ����*.ҽ�ƻ�����չ�ٴ�ҩѧ�������ٴ�ҩʦ������״����[J]. �й�ҩѧ��־, 2013,48(24): 2166-2168
[11] �������.��֢�໤���ٴ�ҩʦ�������ܲ�ȫ���ߵ�ҩѧ�໤[J]. �й�ҩѧ��־, 2013,48(2): 152-154
[12] �ܹ��� �պ� ��ȫӢ ���ı� ��ΰ��.һ��ҩԴ������ɭ�ۺ����ķ��������[J]. �й�ҩѧ��־, 2012,47(7): 565-566
[13] ����.���ڿ��ٴ�ҩʦ�������[J]. �й�ҩѧ��־, 2012,47(5): 391-392
[14] �����������ɣ�ʷ���ң���־��.�ٴ�ҩʦ���������ҩ������ʵ��[J]. �й�ҩѧ��־, 2012,47(19): 1600-1603
[15] ������.�ٴ�ҩʦ���������ڿ��ٴ�����Ⱦ���ư�������[J]. �й�ҩѧ��־, 2012,47(12): 1012-1013
Copyright 2010 by �й�ҩѧ��־